Comparative testing of a subset of 82 IIFT positive samples from 26 COVID-19 patients (dpo range: 10 to 178) with a commercially available, NCP-based indirect ELISA (Euroimmun SARS-CoV-2 NCP IgG) revealed a high concordance with SARS-CoV-2 FcγR IgG ELISA 1 (Fig. S3). The gene discussed is FCGR2A; the disease is COVID-19.